Cerus (NASDAQ:CERS) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?

Shares of Cerus Corporation (NASDAQ:CERS) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.42 and traded as high as $1.78. Cerus shares last traded at $1.7650, with a volume of 658,057 shares traded.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CERS. Weiss Ratings reissued a “sell (e+)” rating on shares of Cerus in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $4.00.

Cerus Trading Up 0.3%

The company has a debt-to-equity ratio of 1.01, a current ratio of 2.00 and a quick ratio of 1.35. The firm has a market cap of $339.04 million, a PE ratio of -17.65 and a beta of 1.67. The company’s 50 day moving average price is $1.57 and its 200 day moving average price is $1.42.

Cerus (NASDAQ:CERS) last announced its earnings results on Thursday, November 6th. The biotechnology company reported $0.00 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.02. Cerus had a negative net margin of 9.81% and a negative return on equity of 33.77%. The firm had revenue of $60.24 million for the quarter, compared to the consensus estimate of $55.12 million. Cerus has set its FY 2025 guidance at EPS. As a group, analysts forecast that Cerus Corporation will post -0.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Cerus

Several large investors have recently bought and sold shares of CERS. Focus Partners Advisor Solutions LLC boosted its stake in shares of Cerus by 65.2% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 19,930 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 7,866 shares during the period. CIBC Bancorp USA Inc. purchased a new position in Cerus in the third quarter worth approximately $31,000. Dynamic Technology Lab Private Ltd acquired a new position in Cerus during the 1st quarter worth approximately $32,000. Aquatic Capital Management LLC purchased a new stake in shares of Cerus in the 3rd quarter valued at approximately $35,000. Finally, HUB Investment Partners LLC acquired a new stake in shares of Cerus in the 2nd quarter valued at $42,000. Hedge funds and other institutional investors own 78.37% of the company’s stock.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.